Phosphatidylinositol 3-kinase class II α-isoform PI3K-C2α is required for transforming growth factor β-induced smad signaling in endothelial cells by Aki Sho et al.
Phosphatidylinositol 3-kinase class II α
-isoform PI3K-C2α is required for
transforming growth factor β-induced smad
signaling in endothelial cells
著者 Aki Sho, Yoshioka Kazuaki, Okamoto Yasuo,
Takuwa Noriko, Takuwa Yoh
journal or
publication title







  Phosphatidylinositol 3-kinase class II α-isoform PI3K-C2α is required for transforming growth factor β-
induced Smad signaling in endothelial cells* 
 
Sho Aki1, Kazuaki Yoshioka1, Yasuo Okamoto1, Noriko Takuwa1,2, and Yoh Takuwa1 
 
1Department of Physiology, Kanazawa University School of Medicine, Kanazawa, Ishikawa 920-8640, 
Japan 




*Running title: Crucial role of PI3K-C2α in TGFβ signaling 
 
To whom correspondence should be addressed: Yoh Takuwa, Department of Physiology, Kanazawa 
University School of Medicine, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan, Tel: +81(76) 
265-2165; Fax: +81(76) 234-4223; E-mail: ytakuwa@med.kanazawa-u.ac.jp 
 
 
Keywords: PI3K-C2α, TGFβ, TGFβ receptor, Smad, SARA, endocytosis, endosomes, endothelial cells, 
vascular endothelial growth factor   
 
Background: TGFβ receptor signals through 
Smad phosphorylation, which is dependent on 
endocytosis of TGFβ receptors and the Smad 
anchor protein SARA localized on endosomes. 
Results: Class II PI3K-C2α is necessary for 
TGFβ receptor endocytosis into SARA–
containing endosomes, SARA–Smad complex 
formation and Smad phosphorylation. 
Conclusion: PI3K-C2α serves endosomal TGFβ 
receptor signaling.  
Significance: PI3K-C2α is a key molecule that is 
generally engaged in  endosomal receptor 
signaling.   
 
ABSTRACT  
We have recently demonstrated that PI3K 
class II-α isoform (PI3K-C2α), which 
generates phosphatidylinositol-3-phosphate  
and phosphatidylinositol-3,4-bisphosphates, 
plays crucial roles in angiogenesis, by 
analyzing PI3K-C2α–knockout mice. The 
PI3K-C2α actions are mediated at least in 
part through its participation in the 
internalization of VEGF receptor-2 and 
sphingosine-1-phosphate receptor S1P1 and 
thereby their signaling on endosomes. TGFβ, 
which is also an essential angiogenic factor, 
signals via the serine/threonine kinase 
receptor complex to induce phosphorylation 
of Smad2 and Smad3 (Smad2/3). Smad 
anchor for receptor activation (SARA) protein, 
which is localized in early endosomes through 
its FYVE domain, is required for Smad2/3 
signaling. In the present study, we showed 
that PI3K-C2α knockdown nearly completely 
abolished TGFβ1−induced phosphorylation 
and nuclear translocation of Smad2/3 in 
vascular endothelial cells (EC). PI3K-C2α was 
necessary for TGFβ−induced increase in 
phosphatidylinositol-3,4-bisphosphates in the 
plasma membrane and TGFβ receptor 
internalization into the SARA−containing 
early endosomes, but not for 
phosphatidylinositol-3-phosphate enrichment 
or localization of SARA in the early 
endosomes. PI3K-C2α was also required for 
TGFβ receptor−mediated formation of 
SARA−Smad2/3 complex. Inhibition of 
dynamin, which is required for the 
clathrin−dependent receptor endocytosis, 
suppressed both TGFβ receptor 
internalization and Smad2/3 phosphorylation. 
TGFβ1 stimulated Smad−dependent VEGF-A 
expression, VEGF receptor−mediated EC 
migration and capillary−like tube formation, 
which were all abolished by either PI3K-C2α 
knockdown or a dynamin inhibitor. Finally, 
TGFβ1−induced microvessel formation in 
Matrigel plugs was greatly attenuated in 
EC−specific PI3K-C2α−deleted mice. These 
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observations indicate that PI3K-C2α plays the 
pivotal role in TGFβ receptor endocytosis and 
thereby Smad2/3 signaling, participating in 




PI3Ks are a family of enzymes that 
phosphorylate membrane inositol phospholipids 
at the 3’ position of the inositol ring, and 
comprise three classes (class I to III) (1, 2). Class 
I PI3Ks, which mainly generate 
phosphatidylinositol-3,4,5-bisphosphates 
(PtdIns(3,4,5)P2), are activated by receptor 
tyrosine kinases and G protein−coupled receptors 
to mediate activation of Akt and Rac, stimulating 
cell proliferation and migration. In contrast to the 
well characterized class I PI3Ks, physiological 
roles of class II PI3Ks, which have three 
members PI3K-C2α, -C2β and -C2γ, were not 
well understood (3-7). We have recently revealed 
that PI3K-C2α plays a crucial role in 
angiogenesis and maintenance of the endothelial 
barrier integrity in an endothelial cell 
(EC)−autonomous manner (8). PI3K-C2α is 
localized in clathrin−coated pits and endocytic 
vesicles, early endosomes and the trans-Golgi 
network (TGN) (8-11) and is thought to 
predominantly generate phosphatidylinositol-3-
phosphate (PtdIns(3)P) and/or 
phosphatidylinositol-3,4-bisphosphates 
(PtdIns(3,4)P2) in vivo differently from class I 
PI3K (3-5, 7, 12-14). Our data showed that 
PI3K-C2α regulates vesicular trafficking in EC 
and thereby is indispensable for vesicular 
transport−mediated delivery of cargos including 
the endothelial adhesion molecule VE-cadherin 
and ligand binding−induced endocytosis of the 
receptor tyrosine kinase VEGF receptor-2 
(VEGFR2) and the G protein−coupled receptor 
S1P1 (8, 15,16). Signaling of VEGFR2 and S1P1 
was defective in PI3K-C2α−depleted EC: the 
receptor endocytosis was inhibited and the 
signaling on endosomes, particularly Rho 
GTPase activation, was impaired. These defects 
result in impaired migration, proliferation and 
intercellular junction formation in EC. It is 
unknown whether and how PI3K-C2α regulates 
signaling of other angiogenic receptors. In 
addition to our studies, a general regulatory role 
for PI3K-C2α in endocytosis through the 
generation of PtdIns(3,4)P2 in the plasma 
membrane was recently reported (14). 
TGFβ is involved in the regulation of 
migration and proliferation of EC, production of 
basement membrane, and differentiation and 
recruitment of mural cells, thus being essential 
for normal vascular formation (17-20). TGFβ 
signals through type I and type II TGFβ-
receptors, which are both serine/threonine 
transmembrane kinases (21-23). TGFβ binds to 
type II receptor, which phosphorylates and 
activates type I receptors, activin receptor-like 
kinase (ALK)1 and ALK5. ALK1 and ALK5 in 
turn phosphorylate the receptor−regulated Smads, 
Smad1 and Smad5 (Smad1/5) and Smad2 and 
Smad3 (Smad2/3), respectively. Phosphorylated 
receptor−regulated Smads form complexes with 
the common mediator Smad4 and the Smad 
complexes translocate into the nucleus to 
regulate gene transcription. It was proposed that 
TGFβ signaling pathways via ALK1 and ALK5 
in EC may play a balancing role for controlling 
proliferation and migration of EC during 
angiogenesis (24, 25). Of the two TGFβ 
signaling pathways, EC−specific gene ablation of 
either ALK5 or Smad2/3 resulted in the similar 
vascular abnormalities, indicating a pivotal role 
of endothelial ALK5−Smad2/3 pathway in the 
angiogenic effect of TGFβ (19, 20, 26,27). Smad 
anchor for receptor activation (SARA) protein 
contains the binding domains for both Smad2/3 
and the TGFβ receptor complex, and is localized 
in the early endosomes through its FYVE domain, 
which specifically recognizes and binds to 
PtdIns(3)P (28). Previous studies (28-31) 
demonstrated that upon TGFβ stimulation, the 
TGFβ receptor complex undergoes clathrin-
dependent endocytosis into the early endosomes 
containing SARA and that the proper localization 
of SARA in the early endosomes and the TGFβ 
receptor internalization into the 
SARA−containing endosomes are the events 
necessary for TGFβ−induced phosphorylation of 
Smad2/3 and the following nuclear translocation 
of the Smad complexes. It is likely that PI3Ks are 
involved in TGFβ receptor internalization, the 
endosomal localization of SARA, and thus TGFβ 
signaling. However, it is unknown which isoform 
of PI3K is engaged in the processes of TGFβ 
signaling.  
In the present study, we studied a role for 
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PI3K-C2α in TGFβ−induced Smad2/3 signaling 
in EC. We found that TGFβ−induced Smad2/3 
phosphorylation, Smad2/3−dependent gene 
expression and angiogenic responses were 
strongly dependent on PI3K-C2α. PI3K-C2α was 
required for TGFβ receptor internalization but 
not the endosomal localization of SARA. These 
observations suggest that PI3K-C2α plays an 




EXPERIMENTAL PROCEDURES  
Cells  
Human umbilical vein endothelial cells 
(HUVEC) (Lonza, Basel, Switzerland), the 
Human microvascular endothelial cells 
(HMVEC) and mouse lung vascular endothelial 
cells (MLEC) were plated onto type-I collagen 
(Nitta Gelatin, Osaka, Japan)−coated  dishes and 
flasks, and allowed to grow under 5% CO2 at 
37 °C in complete endothelial growth medium 
containing 2% fetal bovine serum (FBS) and 
growth factor supplements (EGM-2 (#CC3156, 
Lonza) for HUVEC and EBM-2-MV (#CC4147, 
Lonza) for HMVEC and MLEC). HUVEC 
between passages 4 to 6 were used for all 
experiments. MLEC and mouse aortic smooth 
muscle (MASM) cells were isolated from 
Pik3c2aflox/flox mice and used for in vitro assays as 
described previously (8, 32, 33). HEK293T cells, 
MASM cells and Caco2 cells were cultured in 
10% FBS (Invitrogen Gibco)–supplemented 
DMEM for HEK293T and Caco2 cells (#041-
29775, Invitrogen Gibco, Gaithersburg, MD) and 
advanced DMEM for MASM cells (#12491, 
Invitrogen Gibco). 
 
Small interfering RNA, plasmids and 
transfection  
Knockdown of endogenous PI3K isoforms and 
Smad4 were performed with the siRNAs that 
were synthesized using a Silencers siRNA 
construction kit (#AM1620, Ambion, Austin, 
TX) according to the manufacturer’s instruction. 
The target sequences were: 5’ -
AAGGTTGGCACTTACAAGAAT–3’ and 5’-
AAGTAAGCCTAAGGTGGATAA-3’ for 
human PI3K-C2α #1 and #2, respectively; 5’-
AAGCCGGAAGCTTCTGGGTTT-3’ for PI3K-
C2β; 5’–GGACAACTGTTTCATATAG–3’ for 
class I PI3K p110α; 5’-
AAACTCAACACTGGCTAATTA-3’ for 
Vps34; 5’-AATACATTCCAACTGCACACCC–
3’ for Smad4; 5’- 
GGGGGAAATACGACTTAGTGAGG-3’ for 
ALK5. HUVECs were transfected by incubating 
with the siRNAs in the presence of 
Lipofectamine 2000 (#11668-019, Invitrogen) 
for 48-72 h before the experiments. MASM cells 
isolated from Pik3c2aflox/flox mice were grown to 
70% confluency and then infected with the 
adenovirus encoding Cre recombinase (Ad-Cre) 
in the absence of serum. Adenovirus encoding 
LacZ (Ad-LacZ) was used as control. After 1 h 
of adenovirus infection, the growth medium 
containing 10% FBS was added and the cells 
were allowed to recover for the next 48 h. The 
expression vector for GFP−PI3K-C2α was 
described previously (8). The expression vectors 
for the PI3K-C2α–specific siRNA–resistant form 
of PI3K-C2α (C2αr) and the kinase-deficient  
mutant (D1268A) of GFP−PI3K-
C2α (GFP−kdPI3K-C2α) were generated using a 
standard PCR-based method (34). In C2αr, the 
codons AAG-GTT-GGC-ACT-TAC for the 
amino acids Lys728-Val729-Gly730-Thr731-Tyr732 
were replaced by the nucleotides AAA-GTC-
GGT-ACC-TAT, which encodes the same amino 
acids. The changes in these nucleotides rendered 
C2αr resistant to the PI3K-C2α−specific siRNA. 
The expression vectors for FLAG−tagged wild-
type SARA (wtSARA), FLAG−tagged Smad-
binding domain (the amino acids 665-
704)−deleted SARA mutant (ΔSBD-SARA), 
FLAG−tagged wild-type ALK5 (wtALK5), 
FLAG−tagged constitutively activated mutant 
(T202D) of ALK5 (caALK5) and GFP-PHTAPP1 
were purchased from Addgene (Cambidge, MA). 
The expression vector for GFP-FYVESARA was 
provided by Dr. S. Itoh (Showa Pharmaceutical 
University) (26). The expression vectors for 
FLAG−tagged Smad2 and FLAG−tagged Smad3 
were provided by Dr. K. Miyazono (University 
of Tokyo) (35).  
 
Immunoblotting and immunoprecipitation 
analysis 
At 48 h after siRNA transfection, the cells were 
serum-starved with M199 (Invitrogen Gibco) 
containing 0.5% fatty acid−free BSA (#A6003, 
Sigma-Aldrich, MO) for 4 h and then stimulated 
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with 5 ng/ml TGFβ1 (#240-B, R&D Systems, 
Minneapolis, MN). The cells were washed in 
PBS and lysed in the cell lysis buffer (20 mM 
Tris-HCl pH 7.2, 150 mM NaCl, 1 mM CaCl2, 
0.5 % Triton X-100, 100 mM NaF, 1 mM 
Na3VO4) supplemented with Complete Protease 
inhibitor cocktail (Roche, Basel, Switzerland) by 
scraping, followed by centrifugation for 15 min 
at 16, 000 x g at 4 °C. The resultant supernatants 
were taken and electrophoresed on 8 % SDS- 
PAGE and transferred onto PVDF membrane 
(Millipore, Billerica, MA). The membranes were 
blocked in PBS containing 5% BSA, and 
incubated with respective antibodies overnight. 
The antibodies used are: PI3K-C2α (#611046, 
BD Biosciense, Sane Jose, CA); PI3K-C2β 
(#611342, BD Bioscience); p110α (#4249, Cell 
Signaling, Danvers, MA); Vps34 (#4263, Cell 
Signaling); total Smad2/3 (#610842, BD 
Bioscience); phosphorylated Smad2 (p-Smad2) 
(#3101, Cell Signaling); phosphorylated Smad3 
(p-Smad3) (#9520, Cell Signaling); total ERK1/2 
(#9102, Cell Signaling); phosphorylated ERK1/2 
(#4370, Cell Signaling); total Smad4 (#9515, 
Cell Signaling); SARA (sc-9135, Santa Cruz, 
Dallas, TX); phospho-serine (Invitorgen, 
618100); β-actin (A1978, Sigma-Aldrich). The 
membranes were incubated with alkaline 
phosphatase (AP)–conjugated secondary 
antibodies (anti-mouse IgG antibody, #7056; 
anti-rabbit IgG antibody, #7054) (Cell Signaling) 
and visualized by color reaction using 5-bromo-
4-chloro-3-indolyl-phosphate/nitro blue 
tetrazolium (Wako, Osaka, Japan). The band 
intensities were determined using Image Gauge 
(Fuji film, Tokyo, Japan). The values were 
normalized for the value of β-actin as a loading 
control and expressed as multiples over the 
normalized values of non-treated controls. 
For immunoprecipitation assay, HEK293T 
cells were co-transfected with the expression 
vectors for FLAG-Smad3, either FLAG-SARA 
or FLAG-ΔSBD-SARA, and either FLAG-wild-
type ALK5 or FLAG-constitutively activated  
ALK5 (caALK5), and 72 h later lysed in IP 
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
1% NP-40, 0.5% deoxycholate, 0.1% SDS) 
supplemented with Complete Protease inhibitor 
cocktails. The lysates were incubated with anti-
SARA antibody for 1 h at 4°C with rocking, 
followed by the incubation with protein G-
agarose beads (#1-719-416, Roche) for 1 h at 
4°C. After the beads were washed five times, the 
beads were mixed with 2 x Laemmli’s SDS 
sample buffer and boiled. The resultant samples 





HUVEC were plated onto type-I collagen−coated 
glass bottom dishes (MatTek Corporation, 
Ashland, MA) and allowed to adhere to dishes in 
EGM-2 growth medium overnight. The cells 
were rinsed with pre-warmed PBS once and 
fixed in pre-warmed 4% fresh paraformaldehyde 
(PFA) in PBS for 10 min, washed with PBS, and 
then permeabilized in 0.2 % TritonX-100 in PBS 
for 15 min when necessary. After the cells were 
incubated with 5% normal goat serum for 60 min 
to inhibit non-specific protein binding, the cells 
were incubated with rabbit polyclonal anti-p-
Smad2 antibody (#AB3849, Millipore), mouse 
monoclonal anti-Smad2/3 antibody (#610842, 
BD Biosciences), rabbit polyclonal anti-SARA 
antibody or mouse monoclonal anti-EEA1 
antibody (#610456, BD Biosciences) for 2 h at 
room temperature or overnight at 4°C. The cells 
were incubated for 60 min at room temperature 
with Alexa Fluor 488-conjugated goat anti-
mouse (#A31620, Molecular Probes, Carlsbad, 
CA), Alexa Fluor 488-conjugated goat anti-rabbit 
(#A11034), Alexa Fluor 594−conjugated goat 
anti-mouse (#A31624), Alexa Fluor 
594−conjugated goat anti-rabbit (#A31620) 
secondary antibodies diluted at 1:1000 in PBS. 
Where appropriate, the cells were counterstained 
with 4ʼ, 6-diamidino-2-phenyliindole (DAPI) (# 
D1306, Molecular Probe) for 5 min. The cells 
were mounted on Fluoromount (#K024, 
Diagnostic BioSystems, Pleasanton, CA) and 
observed under a custom confocal microscope 
unit described in detail previously (8). For 
immunohistochemistry of the sections of 
Matrigel plugs, the sections of PFA-fixed, 
paraffin−embedded Matrigel plug were 
deparaffinized and processed in heat−induced 
target retrieval to unmask the antigen using with 
Target Retrieval solution (Dako, Carpinteria, 
CA) (30). The sections were incubated with 
Dako blocking solution (#X0909, Dako) for 10 
min to inhibit non-specific protein binding. After 
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blocking, the sections were stained with rabbit 
polyclonal anti-von Willebrand factor (vWF) 
(#A0082, Dako) for 60 min at room temperature. 
The sections were incubated with the secondary 
antibody of an EnVision kit (#K4002, Dako) for 
60 min and the color reaction was developed. 
Where appropriate, the sections were 
counterstained with hematoxylin. The sections 
were examined using a BX41 inverted 
microscope (OLYMPUS, Tokyo, Japan), and 
vWF−positive microvessel numbers were 
determined with ImageJ software.  
 
Proximity ligation assay (PLA) staining 
The cells were fixed in pre-warmed 4% fresh 
PFA in PBS for 10 min and permeabilized in 
0.2 % TritonX-100 in PBS for 15 min when 
necessary. After the cells were incubated with 
rabbit polyclonal anti-ALK5 antibody (sc-398, 
Santa Cruz), mouse monoclonal anti-Smad2/3 
antibody, mouse monoclonal anti-SARA (sc-
133071, Santa Cruz) antibody overnight at 4°C, 
in situ protein interactions were detected using 
the Duolink proximity ligation assay kit 
according to the manufacturer’s instructions 
(Olink Bioscience, Uppsala, Sweden). The cells 
were stained with anti-EEA1-Alexa Fluor 594 
(M176 A59, MBL, Nagoya, Japan). 
 
RNA isolation and quantitative PCR analysis 
Total RNA in HUVEC was isolated using TRIzol 
reagent (Invitrogen). One μg total RNA was 
reverse-transcribed into the first-strand cDNA 
using QuantiTect RT Kit (#205311, Qiagen, 
Hilden, Germany). Quantitative PCR (qPCR) 
reactions were performed using FAM-conjugated 
TaqMan inventoried assay from Applied 
Biosystems for human PI3K-C2α 
(Hs0090461_m1) and human VEGF-A 
(Hs00900055_m1). 18S-rRNA (Hs99999901_s1) 
probe was used as an internal control. The 
mRNA expression levels were normalized for the 
expression of 18S-rRNA mRNA and the results 
were expressed as multiples over control values. 
Comparative quantitative analysis was performed 
using the GeneAmp 7300 system (Applied 
Bioscience, Foster city, CA) based on delta-delta 
Ct method. 
 
Wound healing/scratch and tube-formation 
assay 
For wound healing/scratch assay (32), confluent 
HUVEC monolayers were scratched with a 
standard 20 μl pipette tip and incubated in M199 
containing 1% FBS in the presence of 
recombinant humanVEGF-A (50 ng/ml) (#100-
20, PeproTech, Rocky Hill, NJ), TGFβ1 (5 
ng/ml), dynasore (80 μM) (#D7693, Sigma-
Aldrich), ALK5 inhibitor II (2-(3-(6-
methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-
naphthyridine) (5 μM) (#616452, Merck-
CalbioChem) and VEGFR2 inhibitor SU1498 
(10 μM) (#572888, Merck-Calbiochem) for 8 h. 
The microphotographs were taken at 0 and 8 h, 
and the wound width was determined with Image 
J software. For tube-formation assays, siRNA-
transfected HUVEC (2.0 x 104 cells) in M199 
containing 1% FBS were seeded onto 200 μl of 
growth factor-reduced Matrigel (BD 
Biosciences) in a 24-well plate in the absence 
and presence of VEGF-A (50 ng/ml), TGFβ1 (5 
ng/ml), dynasore (80 μM), ALK5 inhibitor (5 
μM) and VEGFR2 inhibitor (10 μM), and were 
incubated for 12 h. Tube formation was 
quantified by measuring cumulative tube length 
in five random microscopic fields/well using 
ImageJ software under a BIOREVO microscope 
(Keyence, Osaka, Japan). 
 
Matrigel plug in vivo angiogenesis assay 
All mice used in this study were bred and 
maintained at the Institute for Experimental 
Animals, Advanced Science Research Center, 
Kanazawa University under specific pathogen–
free conditions. All procedures were conducted 
in accordance with the Fundamental Guidelines 
for Proper Conduct of Animal Experiment and 
Related Activities in Academic Research 
Institutions under the jurisdiction of the Ministry 
of Education, Culture, Sports, Science and 
Technology of Japan and approved by the 
Committee on Animal Experimentation of 
Kanazawa University. Pik3c2aΔEC (C2αΔEC) 
(Pik3c2aflox/flox; Cdh5(PAC)-CreERT2) and 
Pik3c2aΔSMC (C2αΔSMC) (Pik3c2aflox/flox; SM22a-
Cre) mice were described previously (8). Cre-
negative littermates were used as controls. To 
verify the efficiency of Cre recombination, Cre 
mice were mated with mice from the Cre reporter 
transgenic line ROSA26-LacZ (B6.129S4-
Gt(ROSA)26Sortm1Sor/J, Jackson Lab). All mice 
had a C57BL/6J genetic background. For 
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Pik3c2a gene inactivation in adult mice, 
tamoxifen (10 mg/ml corn oil) (#T5648, Sigma-
Aldrich) was administered seven times by i.p. 
injection of 100 μl tamoxifen solution. For 
Matrigel plug assay (32, 36), recombinant 
VEGF-A (200 ng/ml), FGF2 (400 ng/ml) (#AF-
100-18B, PeproTech) and heparin (100 mg/ml) 
(Sigma-Aldrich) were mixed with growth factor-
reduced Matrigel. The Matrigel solutions (300 μl 
each) were injected subcutaneously into the groin 
area close to the dorsal midline (most angiogenic 
portion) of anesthetized mice. Matrigel plugs 
were harvested on days 10 and fixed overnight in 
4% PFA for paraffin embedding and the 
following immunohistochemistry. 
 
VEGF-A ELISA assay  
Human VEGF-A protein levels in the 
conditioned media of HUVEC cultures were 
determined using human VEGF-A ELISA 
Immunoassay (#DVE00, R&D systems, 
Minneapolis, MN) according to the 
manufacturer’s protocol. Optical density was 
measured at 450 nm using a 540 nm correction 
with a Multiskan GO (Thermo Fisher Scientific, 
Walyham, MA).  
 
Statistical analysis 
The data are presented as means ± SEM and 
expressed as the percentages or multiples relative 
to the values in control cells. Statistical 
significance was analyzed using Prism 5 software 
(GraphPad Software Inc., San Diego, CA). 
Statistical significance was analyzed either by 
one-way or two-way analysis of variance 
(ANOVA) followed by Bonferroni test as 
appropriate. Results with p < 0.05 were 




TGFβ1−induced phosphorylation and nuclear 
translocation of Smad2/3 are dependent on 
class II PI3K-C2α  
We studied roles of PI3K isoforms in 
TGFβ1−induced Smad2/3 stimulation in vascular 
EC. HUVEC were transfected with either of the 
specific siRNAs against class I PI3K p110α, class 
II PI3K-C2α and PI3K-C2β, and class III Vps34, 
or scrambled siRNA (sc-siRNA) as control. Each 
siRNA effectively inhibited the expression of 
respective PI3K proteins but not other PI3K 
isoform proteins (Fig. 1 A and B). In sc-
siRNA−transfected control HUVEC, TGFβ1 
induced a gradual increase in Smad3 
phosphorylation, which reached the plateau level 
of an 8-fold increase over the basal at 30 min 
(Fig. 1B). Transfection of PI3K-C2α−siRNAs 
(C2α-siRNAs #1 and #2) markedly inhibited 
TGFβ1−induced stimulation of Smad3 
phosphorylation throughout the observation time 
period. TGFβ1 also induced Smad2 
phosphorylation, which was greatly suppressed 
by PI3K-C2α knockdown (Fig. 1C). In contrast, 
knockdown of either p110α, PI3K-C2β or Vps34 
failed to inhibit TGFβ1−induced phosphorylation 
of Smad2/3. TGFβ1 did not stimulate 
phosphorylation of Smad1, Smad5 or Smad8 
(Smad1/5/8) in HUVEC (Fig. 1D). In contrast, 
BMP9 induced phosphorylation of Smad1/5/8 
(Fig. 1E) but not Smad2/3 (data not shown). 
Differently from the case of TGFβ1, PI3K-C2α 
knockdown did not suppress BMP9-induced 
Smad1/5/8 phosphorylation. In addition, PI3K-
C2α knockdown did not alter TGFβ1−induced 
activation of the non-canonical pathway ERK, 
which is known to be independent of Smad2/3 
(37), in HUVEC. Similar to HUVEC, TGFβ1 
stimulated phosphorylation of Smad2/3 in human 
microvascular endothelial cells (HMVEC) and 
mouse lung endothelial cells (MLEC) in a PI3K-
C2α–dependent manner (Fig. 2 A and B). TGFβ1 
also stimulated phosphorylation of Smad1/5/8 in 
HMVEC, which was also dependent on PI3K-
C2α (Fig. 2A). Unlike vascular endothelial cells, 
deletion of PI3K-C2α in mouse aortic smooth 
muscle (MASM) cells and human colonic 
epithelial carcinoma Caco2 cells did not inhibit 
TGFβ1−induced phosphorylation of Smad2/3 
(Fig. 2 C and D). Thus, PI3K-C2α was necessary 
for TGFβ–induced Smad2/3 phosphorylation in 
vascular EC but not in vascular smooth muscle. 
Stimulation with TGFβ1 induced robust 
nuclear translocation of Smad2/3 in sc-
siRNA−transfected HUVEC as evaluated with 
anti-Smad2/3 immunofluorescent staining (Fig. 
3A). We also observed that TGFβ1 stimulated 
nuclear accumulation of p-Smad2, which was 
also markedly suppressed by PI3K-C2α 
knockdown (Fig. 3B). In C2α-
siRNA−transfected HUVEC, the exogenous 
expression of the C2α-siRNA−resistant form of 
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PI3K-C2α (C2αr) but not wild-type PI3K-
C2α (wtC2α) restored TGFβ−induced Smad 
activation (Fig. 3, C and D). In sc-
siRNA−transfected HUVEC, the overexpression 
of wild-type PI3K-C2α by itself did not change 
TGFβ−induced Smad translocation into the 
nucleus. Moreover, we determined the effect of 
the expression of the kinase-deficient mutant of 
C2αr (kdC2αr) on Smad2/3 nuclear translocation. 
In sc-siRNA-transfected control HUVEC, the 
expression of kdC2αr inhibited TGFβ1−induced 
Smad2/3 nuclear accumulation, differently from 
wtC2αr expression (Fig. 3D). In C2α-
siRNA−transfected HUVEC, the expression of 
kdC2αr did not restore TGFβ1-induced Smad2/3 
nuclear accumulation, differently from wtC2αr. 
These observations together suggest that PI3K-
C2α fulfils an indispensable role for 
TGFβ1−induced Smad2/3 activation through its 
kinase activity in EC. 
 
TGFβ1−induced TGFβ-receptor 
internalization into SARA−containing 
endosomes is dependent on PI3K-C2α 
TGFβ1 stimulation induced an increase in serine 
phosphorylation of ALK5 in HEK293T cells 
transfected with wtALK5 (Fig. 4A). In HEK293T 
cells, we observed PI3K-C2α−dependence of 
TGFβ1−induced Smad2/3 phosphorylation (data 
not shown). PI3K-C2α knockdown did not 
inhibit TGFβ-induced serine phosphorylation of 
wtALK5, implying that PI3K-C2α is necessary 
for the TGFβ receptor signaling step, which is 
distal to phosphorylation of type I TGFβ receptor. 
Previous studies (28-31) showed that 
TGFβ1 stimulation triggered clathrin−dependent 
endocytosis of TGFβ receptor and that TGFβ 
receptor endocytosis was required for TGFβ 
activation of Smad2/3 signaling. We tested the 
effect of dynasore, an inhibitor of dynamin which 
is necessary for clathrin−dependent endocytosis, 
in EC. Treatment of HUVEC with dynasore 
abolished TGFβ1−induced phosphorylation of 
Smad2/3, like an ALK inhibitor (Fig. 4B). 
Likewise, the expression of the dominant 
negative dynamin2 mutant but not wild-type 
dynamin2 inhibited nuclear translocation of 
Smad2/3 (Fig. 4C). These observations suggested 
that TGFβ receptor endocytosis was required for 
Smad2/3 signaling. TGFβ1 stimulation promoted 
the internalization of type I TGFβ receptor ALK5 
into the intracellular compartment, which was 
prevented by PI3K-C2α knockdown (Fig. 5A). 
Likewise, dynasore suppressed TGFβ1−induced 
ALK5 internalization. In these immunostainings, 
the anti-ALK5 antibody stained nuclei. ALK5 
knockdown did not abolish or reduce the nuclear 
staining in anti-ALK5 immunostaining (Fig. 5B), 
suggesting that the nuclear staining was non-
specific. In sc-siRNA−transfected HUVEC, the 
expression of kdC2αr partially inhibited 
TGFβ1−induced ALK5 internalization, 
differently from that of wtC2αr expression (Fig. 
5C). In C2α-siRNA−transfected HUVEC, the 
expression of kdC2αr did not restore TGFβ1-
induced ALK5 internalization. Double 
immunofluorescent staining of ALK5 and the 
early endosome marker EEA1 showed that 
TGFβ1 induced the internalization of ALK5 into 
the EEA1-positive early endosomes (Fig. 5D). 
Proximity ligation assay (PLA) staining to detect 
interaction or close colocalization of two 
molecules showed that TGFβ1 stimulation 
induced the close co-localization of ALK5 and 
EEA1 (green dots), which was nearly abolished 
by PI3K-C2α knockdown (Fig. 5E).  
Because SARA is located in the early 
endosomes and acts as a scaffold for Smad2/3 
phosphorylation by ALK5 (28-30), we studied 
the requirement of SARA for TGFβ/ALK5 
signaling, the possible co-localization of TGFβ1 
receptors and SARA, and the effect of PI3K-C2α 
knockdown on the co-localization. Knockdown 
of SARA nearly completely suppressed TGFβ-
induced Smad2/3 phosphorylation (Fig. 6A), 
indicating that SARA is essential for 
TGFβ/ALK5 signaling in HUVEC. Double 
immunofluorescent staining using anti-SARA 
and anti-EEA1 showed that SARA was localized 
mainly in the EEA1−positive early endosome 
compartment in sc-siRNA−transfected HUVEC 
(Figure 6B). TGFβ1 increased the SARA− and 
EEA1−double positive endosomes. PI3K-C2α 
knockdown did not affect the numbers of either 
SARA−positive or EEA1−positive vesicles in 
non-stimulated cells, but abolished 
TGFβ1−induced increase in SARA− and 
EEA1−double positive early endosomes. PLA 
staining for ALK5 and SARA, combined with 
anti-EEA1 immunostaining, showed that TGFβ1 
stimulation induced the close co-localization of 
ALK5 and SARA and that a portion of the 
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closely co-localized ALK5 and SARA existed in 
the EEA1−positive early endosomes (Figure 6C). 
Knockdown of PI3K-C2α inhibited the close co-
localization of ALK5 and SARA in 
EEA1−positive early endosomes. These 
observations indicate that PI3K-C2α is involved 
in TGFβ1−induced ALK5 internalization into the 
SARA−containing endosomes through its kinase 
activity. 
 
Endosomal enrichment of PtdIns(3)P or 
localization of SARA are not dependent on 
PI3K-C2α 
PI3K-C2α was previously reported to generate 
PtdIns(3)P and PtdIns(3,4)P2 in vivo (8,12-14). 
Because SARA is localized in early endosomes 
by binding PtdIns(3)P through its FYVE domain, 
we studied the effects of knockdown of PI3K-
C2α and other PtdIns(3)P−producing PI3K on the 
cellular level and localization of PtdIns(3)P and 
PtdIns(3,4)P2 by observing GFP fluorescence of 
HUVEC that had been transfected with the 
expression vectors for the PtdIns(3)P−specific 
probe GFP-FYVESARA or the 
PtdIns(3,4)P2−specific probe GFP-PHTAPP1. In sc-
siRNA−transfected non-stimulated HUVEC, the 
GFP-FYVESARA signal was a punctate pattern as 
reported previously in non-endothelial cells (29) 
(Fig. 7A), suggesting that PtdIns(3)P was 
enriched in endosomes. TGFβ1 stimulation did 
not change GFP-FYVESARA signal. Among three 
PI3Ks, knockdown of PI3K-C2α did not affect 
GFP-FYVESARA signal. In contrast, that of either 
PI3K-C2β or Vps34 obviously reduced the 
density of vesicular GFP-FYVESARA signals. 
Consistent with these observations, knockdown 
of either PI3K-C2β or Vps34 reduced anti-
SARA−positive endosomes unlike PI3K-C2α 
knockdown, and augmented the diffuse cytosolic 
anti-SARA staining (Fig. 7B), suggesting that 
PI3K-C2β and Vps34 but not PI3K-C2α generate 
PtdIns(3)P in SARA−containing endosomes. 
Thus, PI3K-C2α seems to participate in 
TGFβ−induced signaling, without altering the 
endosomal distribution of SARA. 
In contrast to the effects on PtdIns(3)P level, 
TGFβ1 induced a rapid increase in GFP-
PHTAPP1 signal in lamellipodia (Fig. 7C and 
Supplemental Movies 1-2), suggesting a 
localized increase in the membrane PtdIns(3,4)P2 
level in TGFβ1−stimulated cells. Notably, PI3K-
C2α knockdown abolished TGFβ1−induced 
increase in GFP-PHTAPP1 signals, indicating that 
PI3K-C2α is involved in the generation of 
PtdIns(3,4)P2 in lamellipodia. The recent study 
implicated PI3K-C2α–generated PtdIns(3,4)P2 in 
endocytosis (14). Therefore, it is an interesting 
possibility that PI3K-C2α is involved in TGFβ1–
induced endocytosis of TGFβ-receptor through 
forming PtdIns(3,4)P2 in the plasma membrane. 
 
PI3K-C2α is required for SARA−Smad2/3 
complex formation 
Because SARA is associated with Smad2/3 and 
acts as a scaffold for Smad2/3 phosphorylation 
by type I TGFβ receptor ALK5, we studied the 
PI3K-C2α dependence of SARA−Smad2/3 
complex formation, using anti-SARA 
immunoprecipitation and the following anti-
Smad2/3 immunoblotting. For the experiments, 
we employed HEK293T cells for efficiency of 
gene transduction. We co-transfected HEK293T 
cells with the expression vectors for  either 
wild-type SARA (wtSARA) or the Smad-binding 
domain−deleted SARA mutant (ΔSBD-SARA) 
and either wtALK5 or caALK5, with or without 
Smad2/3 expression vectors. We detected co-
immunoprecipitation of Smad2/3 in the anti-
SARA immunoprecipitates in the cells 
transfected with Smad2/3, wtSARA and wtALK5. 
However, without Smad2/3 transfection we did 
not detect Smad2/3 in the anti-SARA 
immunoprecipitates (Fig. 8A). In sc-
siRNA−treated control cells that had been 
transfected with wtSARA and wtALK5, we 
detected the association of Smad3 and Smad 2 
with SARA (Fig. 8 B and C). The expression of 
caALK5 substantially stimulated the association 
of Smad3 and Smad2 with SARA and resultant 
phosphorylation of Smad3 and Smad2, which 
were both markedly inhibited by the expression 
of ΔSBD-SARA. In contrast, in PI3K-
C2α−depleted cells, caALK5 expression barely 
stimulated the association of Smad3 and Smad2 
with SARA and phosphorylation of Smad3 and 
Smad2. Thus, PI3K-C2α is required for 
ALK5−mediated formation of the SARA and 
Smad2/3 complex and phosphorylation of 
Smad2/3.  
We also studied the interaction of 
endogenous SARA and Smad2/3 in HUVEC 
using PLA staining. TGFβ1 promoted 
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SARA−smad2/3 interaction in the endosomes in 
sc-siRNA-transfected control HUVEC. A portion 
of the PLA signal was colocalized with EEA1, 
indicating that SARA and Smad2/3 complex 
were located in the early endosomes. PI3K-C2α 
knockdown inhibited TGFβ1−stimulated 
SARA−smad2/3 interaction (Fig. 8D). The 
observations indicate that TGFβ1–stimulation of 
the interaction of endogenous SARA and 
Smad2/3 in the endosomes requires PI3K-C2α in 
HUVEC. 
 
PI3K-C2α is required for TGFβ1−induced 
VEGF-A expression in EC 
Consistent with previous studies (38-41), TGFβ1 
increased the expression of mRNA and protein of 
VEGF-A in control HUVEC (Fig. 9, A-C). The 
stimulatory effects of TGFβ1 were inhibited by 
knockdown of the common Smad Smad4, 
suggesting the involvement of Smad2/3. 
Furthermore, TGFβ1−induced VEGF-A 
expression was abolished by the pharmacological 
blockade of ALK5 (Fig. 9D). These observations 
together suggested that TGFβ1−induced VEGF-
A upregulation was dependent on ALK5−Smad 
pathway. In agreement with the involvement of 
the canonical Smad pathway in TGFβ1−induced 
VEGF-A expression, knockdown of PI3K-C2α 
but not PI3K-C2β, p110α or Vps34 inhibited 
TGFβ1−induced VEGF-A expression (Fig. 9, A -
C). Moreover, treatment of HUVEC with 
dynasore abolished TGFβ1−induced VEGF-A 
mRNA expression with suppression of Smad3 
phosphorylation (Figs. 4B and 9C). These 
findings indicate that PI3K-C2α− and 
endocytosis−dependent Smad2/3 signaling 
mediates TGFβ−induced VEGF-A expression in 
EC.  
 
PI3K-C2α is required for TGFβ1−induced 
endothelial cell migration, tube formation and 
in vivo angiogenesis  
In a wound healing assay, PI3K-C2α knockdown 
inhibited migration of HUVEC induced by either 
TGFβ1 or VEGF-A (Fig. 10, A and B). The 
ALK5 inhibitor suppressed TGFβ1−induced cell 
migration. Interestingly, the inhibitor of 
VEGFR2 suppressed not only VEGF−induced 
but TGFβ1−induced cell migration, indicating 
that TGFβ1−induced cell migration is dependent 
on VEGFR2. Likewise, PI3K-C2α knockdown 
inhibited tube formation induced by either 
TGFβ1 or VEGF-A (Fig. 10, C and D). The 
inhibition of VEGF-A−induced tube formation 
by PI3K-C2α knockdown is most likely because 
VEGFR2 signaling is dependent on PI3K-C2α as 
we demonstrated previously (8). The ALK5 
inhibitor and the VEGFR2 inhibitor blocked 
TGFβ1−induced tube formation (Fig. 10, E and 
F). In addition, dynasore suppressed 
TGFβ1−induced tube formation. These 
observations suggest that TGFβ1−induced, 
ALK5−mediated stimulation of endothelial 
migration and morphogenesis is dependent on 
stimulation of VEGF-A expression and VEGFR2 
signaling, in which PI3K-C2α and endocytic 
process are involved.  
We finally investigated a role for PI3K-C2α 
in in vivo angiogenesis, using a Matrigel plug 
assay in conditional PI3K-C2α−knockout mice. 
We subcutaneously injected Matrigel plug with 
or without TGFβ1 in mice with endothelial 
specific deletion of PI3K-C2α (C2αΔEC) or 
smooth muscle−specific PI3K-C2α deletion 
(C2αΔSMC), and compared angiogenesis in both 
mutant mice with that in control mice (C2αflox/flox). 
The inclusion of TGFβ1 in Matrigel increased 
the formation of anti-von Willebrand factor 
(vWF)−positive microvessels in Matrigel plugs 
in control mice, compared with vehicle (Fig. 11, 
A-F). In contrast, in C2αΔEC mice TGFβ1 failed 
to stimulate microvessel formation. In C2αΔSMC 
mice, however, TGFβ1 stimulated microvessel 
formation in Matrigel plugs to the similar extent 
as in control mice (Fig. 11, D-F). We performed 
double immunofluorescent staining of p-Smad2 
and EC marker CD31 in Matrigels containing 
either TGFβ or vehicle that had been implanted 
in C2α∆EC and C2α∆SMC mice. C2α∆EC mice 
showed much reduced p-Smad2− and 
CD31−double positive cells compared with 
C2α∆SMC (Fig. 11G), suggesting that Smad2 
activation in EC was attenuated in C2α∆EC mice. 
These observations suggest that TGFβ1-induced 
microvessel formation in Matrigel plugs is 
dependent on PI3K-C2α that is expressed in EC 




Accumulated evidence indicates that TGFβ 
receptor−Smad2/3 signaling is dependent on the 
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endocytosis of the TGFβ receptor complex (28-
31). Upon TGFβ binding, TGFβ receptors are 
internalized into early endosomes, where the 
Smad anchor SARA is enriched through its 
FYVE domain. SARA interacts with Smad2/3, 
facilitating Smad2/3 phosphorylation and thereby 
their nuclear translocation. PI3K may be 
involved in at least two steps of these TGFβ 
receptor signaling processes: TGFβ−induced 
TGFβ receptor−internalization and the 
endosomal localization of SARA. In the present 
study, we identified class II PI3K-C2α as PI3K 
isoform that is engaged in TGFβ−induced 
activation of Smad2/3 signaling. Our data 
indicate that PI3K-C2α is required for the 
endocytosis of TGFβ receptor but not for 
endosomal localization of SARA. 
The present observation in EC that 
TGFβ−induced Smad2/3 phosphorylation is 
dependent on TGFβ receptor internalization into 
the EEA1−positive, SARA−containing early 
endosomes (Figs. 4-6) is similar to the previous 
observations in other types of cells including 
HeLa cells, HepG2 cells and Mv1Lu cells (28, 30, 
31) although some discrepant results on the 
necessity of SARA for ALK5/Smad2/3 signaling 
were reported (42, 43). Either PI3K-C2α 
depletion (approximately 80~90%) or the 
expression of the kinase-deficient Cα mutant 
strongly suppressed the internalization of TGFβ 
receptor, like the dynamin inhibitor dynasore 
(Fig. 5). Since either PI3K-C2α depletion or 
dynasore markedly inhibited TGFβ−induced 
Smad2/3 phosphorylation (Figs. 1B,C and 4B), 
there is a good correlation between 
TGFβ−induced TGFβ receptor internalization 
and Smad2/3 phosphorylation. As discussed in 
detail below, PI3K-C2α depletion did not 
compromise the endosomal distribution of the 
Smad anchor SARA.   Based on these findings, it 
is reasonable to suggest that PI3K-C2α is 
involved in TGFβ receptor−activated Smad2/3 
signaling largely through regulating TGFβ 
receptor internalization. In addition, the 
overexpression of wtC2α did not affect TGFβ-
induced Smad2/3 activation or ALK5 
internalization, suggesting that the endogenous 
level of wtC2α was sufficient for full activation 
of TGFβ receptor−induced Smad2/3 signaling. 
   We recently demonstrated in EC that ligand 
binding−triggered endocytosis of two different 
classes of cell surface receptors, VEGFR2 and 
S1P1, was dependent on PI3K-C2α (8, 15). 
Interestingly, PI3K-C2α depletion inhibited only 
a part of multiple signaling pathways activated 
by VEGF and S1P: Rho activation in VEGF 
signaling and Rac activation in S1P signaling. 
We observed using Fluorescence Resonance 
Energy Transfer (FRET) imaging technique that 
both VEGF−induced Rho activation and 
S1P−induced Rac activation occurred in 
PtdIns(3)P−enriched endosomes as well as the 
plasma membrane. The present study together 
with those previous observations indicate that 
PI3K-C2α participates in signaling on the 
endosomes, upon the activation of different 
classes of receptors including receptor tyrosine 
kinases, G protein−coupled receptors and 
receptor serine/threonine kinases. Thus, the 
ability of PI3K-C2α to regulate the endocytosis 
of different classes of cell surface receptors 
controls endosomal signaling.   
A recent study (14) suggested a novel 
mechanism about a general role of PI3K-C2α in 
clathrin–dependent endocytosis in non-vascular 
cells; the formation of PtdIns(3,4)P2 by PI3K-
C2α at clathrin–coated pits and late endocytic 
intermediates before dynamin–mediated fission 
recruited the PtdIns(3,4)P2–effector protein 
SNX9, promoting maturation of clathrin–coated 
pits toward endocytic vesicles. They suggested 
that PI3K-C2α formed PtdIns(3,4)P2 from 
PtdIns(4)P, which was generated through 5’–
dephosphorylation of PtdIns(4,5)P2 enriched in 
the clathrin–coated pits. We observed that 
TGFβ1 induced the rapid and sustained 
formation of lamellipodia with a local 
lamellipodial increase in PtdIns(3,4)P2 (Fig. 7C). 
In the lamellipodial region of the plasma 
membrane, endocytosis carries membrane-
anchored Rho GTPases and integrins to the cell 
interior and these molecules are recycled to the 
specific regions of the plasma membrane, which 
promotes lamellipodial protrusion (44). 
Considering the rapid onset of TGFβ1–induced 
lamellipodial formation and an increase in 
PtdIns(3,4)P2 level, these responses very likely 
represent non–genomic effects of TGFβ1. It 
remains to be clarified how TGFβ  induces a 
rapid increase in the level of PtdIns(3,4)P2 
through a mechanism involving PI3K-C2α in EC.    
The interaction of the FYVE domain in 
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SARA with PtdIns(3)P, a predominant 
phosphoinositide in the endosomes, serves the 
endosomal localization of SARA (28, 29, 45). 
Previous studies (12, 46) showed that PI3K-C2α 
formed PtdIns(3)P in cells. These observations 
together with the finding of the endosomal 
localization of PI3K-C2α (8) suggested that 
PI3K-C2α might be responsible for enrichment 
of PtdIns(3)P in the endosomes. However, the 
present study showed that PI3K-C2α depletion 
did not reduce PtdIns(3)−enriched endosomes 
(Fig. 7A). Instead, knockdown of either PI3K-
C2β or Vps34 reduced PtdIns(3)−enriched 
endosomes. In agreement with these findings, 
knockdown of PI3K-C2β or Vps34 but not PI3K-
C2α reduced SARA−containing vesicles (Fig. 
7B). Our observations of the effects of PI3K-C2β 
and Vps34 depletion on SARA distribution are 
consistent with the previous reports showing that 
the non-selective PI3K inhibitor wortmannin 
totally changed the endosomal localization of 
SARA to a diffuse cytosolic pattern with 
inhibition of Smad signaling at the relatively low 
concentrations of 50~100 nM (29, 45). This 
range of concentration of wortmannin does not 
effectively inhibit PI3K-C2α because PI3K-C2α 
is relatively resistant to wortmannin compared 
with the other PI3K (5, 7, 47). Thus, PI3K-C2α 
is not a major enzyme to be responsible for the 
accumulation of PtdIns(3)P in the SARA–
localized vesicular compartment. Our data 
indicate that the other PI3K including class II 
PI3K-C2β and class III Vps34 are involved in 
PtdIns(3)P accumulation in this compartment. 
Another point of interest is that partial reductions 
(25~30%) of SARA association with the 
endosomes by depletion of either PI3K-C2β or 
Vps34 (Fig. 7B) did not inhibit Smad2/3 
phosphorylation (Fig. 1C), which suggests that 
such partial reductions of the SARA association 
with the endosomes do not compromise Smad 
signaling.  
   We observed that PI3K-C2α depletion 
suppressed TGFβ−induced Smad2/3 signaling in 
several different vascular EC of human and 
mouse origins, but not vascular smooth muscle or 
epithelial cells (Figs. 1 and 2). In addition, 
Smad2/3 phosphorylation mediated by caALK5 
in HEK293 cells was also PI3K-C2α–dependent 
(Fig. 8). Therefore, there appears to be some cell-
type specificity concerning the PI3K-C2α–
dependence. A few explanations for this may be 
possible. Another class II PI3K member PI3K-
C2β possesses the similarities to PI3K-C2α, in 
the distribution of the expression, the structure, 
the clathrin-binding capacity and the substrate 
specificity (7). Functionally, PI3K-C2β is 
necessary for growth factor signaling (48) and 
cell migration with its lamellipodial distribution 
(49). Therefore, in vascular smooth muscle cells 
and epithelial cells, PI3K-C2β may be able to 
compensate for PI3K-C2α depletion. 
Alternatively, it might be possible that 
TGFβ−induced Smad2/3 signaling could be cell 
type−specific, because it was reported that the 
dependence of Smad2/3 signaling on endocytosis 
differed, depending on cell types (50).           
In EC, TGFβ−induced activation of Smad2/3 
signaling pathway is linked to the upregulation of 
VEGF-A gene expression (39, 41). Consistent 
with the essential role of PI3K-C2α in 
TGFβ−induced Smad signaling activation, TGFβ 
stimulation of VEGF-A expression was 
completely and specifically dependent on PI3K-
C2α (Fig. 9). Interestingly, TGFβ−induced 
endothelial cell migration and tube formation 
were both dependent on VEGFR2 (Fig. 10). It is 
reasonable to conceive that VEGF-A−stimulated 
cell migration and tube formation requires PI3K-
C2α because VEGFR2 signaling and transport of 
VE-cadherin and other molecules are dependent 
on vesicular trafficking (8, 51). Hence, 
TGFβ−induced stimulation of these cellular 
responses requires PI3K-C2α at least at two steps, 
i.e. TGFβ−induced Smad2/3 
signaling−dependent VEGF expression and 
VEGF activation of VEGFR2 signaling. PI3K-
C2α has a significant in vivo functional role in 
TGFβ−induced neovessel formation at an 
organismal level as demonstrated by the 
observations in EC−specific PI3K-C2α−deleted 
mice (Fig. 12). 
Previous studies showed that TGFβ 
stimulated proliferation and migration of ECs via 
ALK1 whereas TGFβ inhibited proliferation and 
migration of ECs via ALK5 (24, 52) although 
some studies (41, 53) showed that ALK5 
mediated stimulation of cell migration. The 
present observations suggest that ALK5− 
mediated stimulation of EC migration involves 
an indirect mechanism, i.e. stimulation by 
autocrine/paracrine VEGF. TGFβ-induced 
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phosphorylation of Smad1/5/8 was dependent on 
PI3K-C2α as well as Smad2/3 phosphorylation 
(Fig. 2A). It is intriguing to see how 
ALK1−mediated Smad1/5/8 phosphorylation is 
dependent on PI3K-C2α in a future study.  
In summary, the present study indicates that 
PI3K-C2α is indispensable for TGFβ−induced 
Smad signaling through being engaged in the 
internalization of TGFβ receptors into the Smad 
anchor SARA−containing early endosomes. Thus, 
our study suggests that PI3K-C2α is essential for 
endosomal signaling of TGFβ receptors. The 
elucidation of the role for PI3K-C2α in TGFβ 
receptor signaling opens the new avenue for 
understanding normal TGFβ actions in more 
depth and their derangements in diseases.   
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Figure 1. PI3K-C2α is required for TGFβ1–induced Smad2/3 phosphorylation in EC. (A) siRNA–
mediated knockdown of PI3K isoforms. HUVEC were transfected with either of PI3K-C2α#1 (C2α#1)-, 
PI3K-C2β (C2β)-, p110α-, Vps34- and Smad4-specific siRNA or scrambled (sc)-siRNA, and the 
expression of the PI3K proteins, Smad4 and β-actin as a loading control was analyzed with 
immunoblotting. Upper, representative blots. Lower, quantified data. (B) Time–dependent 
phosphorylation of Smad3 in response to TGFβ1 in C2α#1, C2α#2 or sc-siRNA transfected HUVEC. 
Serum-starved cells were stimulated with TGFβ1 (5ng/mL) for the indicated time periods. The cell lysates 
were subjected to immunoblot analysis for phosphorylated Smad3 (p-Smad3) and total Smad2 and Smad3. 
Upper, Effects of siRNA–mediated knockdown of PI3K-C2α. Lower, representative blots of Smads. 
Right, quantified data. (C) Effects of knockdown of PI3K isoforms on TGFβ1–induced Smad2 and 
Smad3 phosphorylation. HUVEC that had been transfected with either of C2α#1-, C2β-, p110α-, and 
Vps34-specific siRNAs or sc-siRNA were stimulated with TGFβ1 (5 ng/ml) for 30min, followed by the 
immunoblot analysis for p-Smad2, p-Smad3, and total Smad2 and Smad3. Upper, representative blots. 
Lower, quantified data. (D) Time–dependent phosphorylation of Smad1/5/8 in response to TGFβ1 in 
HUVEC. The cells were treated as in (B). The cell lysates were subjected to immunoblot analysis for 
phosphorylated Smad1/5/8 (p-Smad1/5/8) and total Smad5. (E) Time–dependent phosphorylation of 
Smad1/5/8 in response to BMP9 in HUVEC. Serum-starved cells were stimulated with BMP9 (10 ng/mL) 
for the indicated time periods. The cell lysates were subject to immunoblot analysis for p-Smad1/5/8, and 
total Smad5. In (A) – (E), the data are means ± SEM of 3-4 determinations (n = 3 or 4.). From Fig. 1 to 
Fig. 12, the asterisks indicate statistical significance between the indicated groups at the levels of *: p < 
0.05, **: p < 0.01 and ***: p < 0.001. ns, statistically not significant.  
 
Figure 2. PI3K-C2α is required for TGFβ–1induced Smad2/3 phosphorylation in EC but not 
smooth muscle cells or epithelial cells. (A) TGFβ1–induced time–dependent phosphorylation of 
Smad2/3 and Smad1/5/8 in human microvascular endothelial cells (HMVEC). Serum-starved cells were 
stimulated with TGFβ1 (5 ng/mL) for the indicated time periods. The cell lysates were subjected to 
immunoblot analysis for p-Smad1/5/8 and p-Smad2/3. (B) Effects of Cre–mediated deletion of C2α on 
TGFβ1–induced Smad3 phosphorylation in mouse lung endothelial cells (MLEC). The cells were 
infected with adenoviruses encoding LacZ (Ad-LacZ) or Cre recombinase (Ad-Cre), and stimulated as in 
(A) and analyzed for p-Smad3. (C) Effects of Cre–mediated deletion of C2α on TGFβ1–induced Smad3 
phosphorylation in mouse aortic smooth muscle (MASM) cells. The cells were treated and analyzed as in 
(A). (D) Effects of knockdown of PI3K isoforms on TGFβ1–induced phosphorylation of Smad2/3. Caco2 
were treated and analyzed as in (A). In (A) – (D), upper, representative blots; lower, quantified data. n = 
3~5. The data are expressed as multiples relative to the values in TGFβ1–nonstimulated sc-
siRNAtransfected cells or Ad-Cre transfected cells. 
 
Figure 3. TGFβ1–induced nuclear translocation of Smad2/3 depends on PI3K-C2α in EC. (A) and 
(B), Immunofluorescent staining of Smad2/3 (A) and p-Smad3 (B) in TGFβ1–stimulated HUVEC. The 
cells were transfected with C2α#1 siRNA or sc-siRNA and stimulated with TGFβ1 (5 ng/ml) for 30 min, 
followed by anti-Smad2/3 antibody or anti-p-Smad3 antibody staining. Nuclei were stained by DAPI. Left, 
representative confocal images of the stained cells. Right, quantified data. The data were obtained from 48 
cells per group. Scale bar, 20 μm. (C) HUVEC were transfected with either wtC2α or C2α-siRNA–
resistant C2α (C2αr) and either C2α#1 siRNA or sc-siRNA. The cells were stimulated with TGFβ1 (5 
ng/ml) for 30 min, followed by immunoblot analysis for p-Smad3. Left, representative blots. Right, 
quantified data. n = 3. (D) HUVEC were transfected with either GFP-wtC2α, GFP-C2αr or GFP-tagged 
kinase deficient mutant of C2αr (GFP-kdC2αr) and either C2α-specific siRNA or sc-siRNA. The cells 
were stimulated with TGFβ1 (5 ng/ml) for 30 min, followed by immunofluorescent staining with anti-
Smad2/3. Nuclei were stained by DAPI. Scale bar, 20 μm. The symbol (#) denotes the transfected cells. 
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Figure 4. TGFβ signaling requires PI3K-C2α distally to TGFβ1–induced ALK5 phosphorylation 
and endocytosis. (A) Effects of C2α–depletion on TGFβ1–induced ALK5 phosphorylation. Left, 
representative blots. Right, quantified data. HEK293T cells were transfected with either FLAG–wtALK5 
or FLAG–caALK5 and either C2α#1 siRNA or sc-siRNA. The cell lysates were immunoprecipitated with 
anti-Flag antibody, followed by immunoblotting (IB) using anti-Flag and anti-phosphoserin (pSer) 
antibodies. A portion of the cell lysates were analyzed for the expression of the indicated proteins with IB. 
IP, immunoprecipitation. The data are from three-independent experiments, which yielded comparable 
results, and expressed as multiples over the values in wtALK5 expressed in sc-siRNA–transfected cells. 
(B) Effects of the endocytosis inhibitor dynasore and the ALK5 inhibitor (iALK5) on TGFβ1induced–
Smad3 phosphorylation. The cells were pre-pretreated or not with dynasore (80 μM) or ALK5 inhibitor (5 
μM) for 30 min and stimulated with TGFβ1 (5 ng/ml) for 30 min. n = 5. (C) Effects of the expression of 
RFP–wild type dynamin2 (RFP–wtDyn2) or RFP–dominant negative dynamin2 (RFP–dnDyn2) on 
TGFβ1–induced nuclear translocation of Smad2/3. The cells were transfected with the RFP-wtDyn2 or 
RFP-dnDyn2 expression vectors and stimulated with TGFβ1 (5 ng/ml) for 30 min, followed by anti-
Smad2/3 immunostaining. Nuclei were stained by DAPI. The arrowheads denote the transfected cells. 
Scale bar, 20 μm. 
 
Figure 5. PI3K-C2α is required for TGFβ1–induced internalization of TGFβ receptor into the early 
endosomes in EC. (A) Effects of C2α–depletion or dynasore on TGFβ1−induced internalization of 
endogenous ALK5. The cells were either transfected with C2α#1 siRNA or sc-siRNA or pretreated with 
dynasore (80 μM) for 30 min, and stimulated with TGFβ1 (5 ng/ml) for 30 min. Left, representative 
confocal images of the stained cells. Right, quantified data of fluorescence intensity per cell that were 
obtained from 24 cells per group. Nuclei were stained by DAPI. Scale bar, 20 μm. (B) Effects of ALK5 
knockdown on the nuclear staining in anti-ALK5 immunostaining. HUVEC were transfected with ALK5-
specific siRNA (ALK5-siRNA) or sc-siRNA, followed by anti-ALK5 immunofluorescent staining. Nuclei 
were stained by DAPI. Scale bar, 20 µm. The symbol (#) denotes the non-specific nuclear signals. (C) 
Effects of the expression of a kinase-deficient C2α mutant on TGFβ1−induced ALK5 internalization. 
HUVEC were transfected with either GFP–C2αr or GFP–kdC2αr and either C2α#1 siRNA or sc-siRNA. 
The cells were stimulated with TGFβ1 (5 ng/ml) for 30 min, followed by immunofluorescent staining with 
anti-ALK5 antibody. Nuclei were stained by DAPI. The symbol (#) denotes the transfected cells. (D) 
Double immunofluorescent staining of ALK5 (green) and EEA1 (red) in TGFβ1–stimulated HUVEC. The 
cells were transfected with C2α#1 siRNA or sc-siRNA, and stimulated with TGFβ1 (5 ng/ ml) for 30 min. 
Left, representative confocal images of the stained cells. Magnified views of the boxed areas are also shown. 
Nuclei were stained by DAPI. Scale bar, 20 μm. Right, quantified data of the ALK5/EEA1-double positive 
vesicle numbers per cell that were obtained from 24 cells per group. (E) Proximity ligation assay (PLA) 
staining of ALK5 and EEA1 (green) in TGFβ1–stimulated HUVEC. The cells were transfected with C2α#1 
siRNA or sc-siRNA, and stimulated with TGFβ1 (5 ng/ ml) for 30 min. Nuclei were stained by DAPI. 
Upper, representative confocal images of the stained cells. Scale bar, 20 μm. Lower, quantified data of the 
numbers of ALK5/EEA1 interactions per cell that were obtained from 24 cells per group. 
 
Figure 6. PI3K-C2α is required for TGFβ receptor internalization into SARA–containing 
endosomes in EC. (A) Effects of SARA depletion on TGFβ1–induced Smad2/3 phosphorylation in 
HUVEC. The cells were transfected with SARA-specific siRNA or sc-siRNA. Serum-starved cells were 
stimulated with TGFβ1 (5ng/mL) for the indicated time periods and subjected to immunoblot analysis for 
p-Smad2, p-Smad3, and total Smad2 and Smad3. Left, representative blots. Right, quantified data. n = 3. 
(B) Double immunofluorescent staining of EEA1 (red) and SARA (green) in TGFβ1–stimulated HUVEC. 
The cells were transfected with C2α#1 siRNA or sc-siRNA, and stimulated with TGFβ1 (5 ng/ ml) for 30 
min. Nuclei were stained by DAPI. Right, Quantified data of the numbers of SARA (upper), EEA1 
(middle), and SARA/EEA1-double (lower) positive vesicle numbers per cell that were obtained from 48 
cells per group. Scale bar, 20 μm. (C) PLA staining (green) of ALK5 and SARA and anti-EEA1 
immunostaining (red) in TGFβ1–stimulated HUVEC. The cells were transfected with C2α#1 siRNA or 
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sc-siRNA and stimulated with TGFβ1 (5 ng/ ml) for 30 min. Left, representative confocal images of the 
stained cells. Green and red denote PLA signals and immunostaining signals, respectively. Nuclei were 
stained by DAPI. Scale bar, 20 μm. Right, quantified data of the numbers of PLA signals (left) and PLA 
signal/anti-EEA1-double positive vesicle numbers per cell (right) that were obtained from 24 cells per 
group. 
 
Figure 7. PI3K-C2α is not required for PtdIns(3)P−enrichment or the localization of SARA in the 
endosomes but for TGFβ−induced increase in PtdIns(3,4)P2 in lamellipodia. (A) GFP-FYVESARA 
fluorescence. The HUVEC were co-transfected with the GFP-FYVESARA expression vector and either 
C2α#1 siRNAs or sc-siRNA, and stimulated with TGFβ1 (5 ng/ml) for 30 min or non-treated. Nuclei 
were stained by DAPI. Left, representative confocal images. Right, quantified data of the numbers of 
GFP-FYVE fluorescence−positive vesicles per cell that were obtained from 48 cells per group. (B) Anti-
SARA immunofluorescent staining. The HUVEC were transfected with either C2α-siRNAs or sc-siRNA, 
and stimulated with TGFβ1 (5 ng/ml) for 30 min or non-treated. Nuclei were stained by DAPI. Left, 
representative confocal images. Right, quantified data of anti-SARA−positive vesicles per cell that were 
obtained from 48 cells per group. Scale bar, 20 μm. (C) GFP-PHTAPP1 fluorescence. The HUVEC were co-
transfected with the GFP-PHTAPP1 expression vector and either C2α-siRNAs or sc-siRNA, and stimulated 
with TGFβ1 (5 ng/ml) for 30 min or non-treated. Nuclei were stained by DAPI. Confocal images at 2,5 
and 10 min after the additions of TGFβ1 or vehicle are shown. 
 
 
Figure 8. SARA-Smad3 complex formation is dependent on PI3K-C2α. (A), (B) and (C), analyses of 
complex formation between SARA and Smad2/3 by coimmunoprecipitaion−immunoblotting in 
HEK293T cells. (A) The cells were transfected with the expression vectors for either wtSARA or ΔSBD-
SARA and either wtALK5 or caALK5, with or without Smad2/3 expression vectors. The cell lysates were 
immunoprecipitated with anti-SARA antibody, followed by immunoblotting (IB) using anti-SARA, anti-
Smad3 or anti-Smad2 antibody. (B) and (C) The cells were co-transfected with the expression vectors for 
either Smad2 or Smad3, either wtSARA or ΔSBD-SARA, either wtALK5 or caALK5, and either C2α#1 
siRNA or sc-siRNA. The cell lysates were immunoprecipitated with anti-SARA antibody, followed by IB 
using anti-SARA, anti-Smad3 antibody in (B) and anti-Smad2 antibody in (C). Portions of the cell lysates 
were analyzed for the expression of the indicated proteins with IB (Input). IP, immunoprecipitation; Ctrl, 
control. Left, Represenative blots. Right, Quantified data of the amounts of Smad3 and Smad2 in 
immunoprecipitates from the cells transfected as indicated. The data are means ± SEM from four 
independent experiments, which yielded comparable results, and expressed as multiples over the values in 
wtALK5– and sc-siRNA–transfected cells. (D) PLA staining of SARA and Smad2/3 (green) and anti-
EEA1 immunostaining (red) in TGFβ1–stimulated HUVEC. The cells were transfected with C2α#1 
siRNA or sc-siRNA, and stimulated with TGFβ1 (5 ng/ ml) for 30 min. Left, representative confocal 
images of the stained cells. Green and red denote PLA signals and immunostaining signals, respectively. 
Nuclei were stained by DAPI. Scale bar, 20 μm. Right, quantified data of the numbers of PLA signals 
(left) and PLA signal/anti-EEA1 staining–double positive vesicle numbers per cell (right) that were 
obtained from 24 cells per group. 
 
 
Figure 9. PI3K-C2α is required for TGFβ1–induced, Smad–dependent VEGF-A production in EC. 
HUVEC were transfected with either of C2α(#1), C2β, p110α, Vps34 and Smad4–specific siRNA or sc-
siRNA, and stimulated with TGFβ1 in the presence and absence of the indicated inhibitors. (A) VEGF-A 
(VEGFA) mRNA expression in the cells stimulated with TGFβ1 (5 ng/ml) for 6 h. The VEGFA mRNA 
expression levels were determined with real-time PCR and were corrected for 18S-rRNA level. n = 6. (B) 
VEGFA mRNA expression in the cells were transfected with either of C2α#1, C2α#2 and sc-siRNA, and 
stimulated with TGFβ1 (5 ng/ml) for 6 h. The VEGFA mRNA expression levels were determined with 
real-time PCR and were corrected for 18S-rRNA level. n = 3. (C) VEGF-A peptide concentrations in the 
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media of the cells stimulated with TGFβ1 (5 ng/ml) for 12 h. n = 3. (D) Effects of dynasore and ALK5 
inhibitor on VEGFA mRNA expression. The cells were pre-pretreated or not with dynasore (80 μM) or 
iALK5 (5 μM) for 30 min and stimulated with TGFβ1 (5 ng/ml) for 6 h. n = 5. In (A) ~ (D), the data are 
expressed as multiples over the values in TGFβ1–nonstimulated sc-siRNA-transfected or vehicle-treated 
control cells. 
 
Figure 10. TGFβ1–induced endothelial cell migration and tube formation are VEGFR2–mediated 
and PI3K-C2α–dependent. (A) and (B) Effects of inhibitors of VEGFR2 and ALK5 on TGFβ1– and 
VEGF–induced cell migration. HUVEC were stimulated with TGFβ1 (5 ng/ml) or VEGF (50 ng/ml) in 
the presence and absence of iALK5 (5 μM) and the VEGFR2 inhibitor (iVEGFR2) (10 μM). Cell 
migration was determined with scratch wounding healing assay. Representative microscopic views (A) 
and quantified data (B). n = 4. (C) and (D) Effects of C2α-knockdown on TGFβ1– and VEGF–induced 
tube formation. siRNA-transfected cells were stimulated with VEGF-A (50 ng/ml) or TGFβ1 (5 ng/ml) 
for 12 h. Representative microscopic views (C) and quantified data (D). n = 4. (D) and (F) Effects of 
dynasore (80 μM), iVEGFR2 (10 μM) and iALK5 (5 μM) on TGFβ1– and VEGF–induced tube formation. 
Representative microscopic views (D) and quantified data (F). n = 4. 
 
Figure 11. Endothelial PI3K-C2α is necessary for TGFβ1–induced angiogenesis in vivo. Matrigels 
containing of PBS (vehicle) or TGFβ1 were injected into the subcutaneous tissues on the back of EC-
specific C2α-deleted (C2αΔEC), SMC-specific C2α-deleted (C2αΔSMC) and control (C2αflox/flox) mice. 
Matrigel plugs were removed ten days later and analyzed for microvascular formation by 
immunohistochemistry using anti-von Willebrand Factor (vWF) antibody. (A and D), representative 
views of anti-vWF immunostained sections of Matrigel plugs in C2αΔEC (A) and C2αΔSMC (D) mice. (B 
and E), quantified data of neovessel formation in Matrigel plugs. 7 mice per group. (C and F), 
representative gross views of Matrigel plugs resected from mice. (G) Double immunofluorescent 
staining of CD31 (red) and p-Smad2 (green) in Matrigel plugs in C2αΔEC (left) and C2αΔSMC (right) mice. 
Nuclei were stained by DAPI. Scale bar, 50 μm. 
 
Figure 12. Receptor endocytosis and ALK5 are necessary for TGFβ1–induced angiogenesis in vivo. 
Matrigels containing of PBS (vehicle) or TGFβ1 and dynasore (200 μM) or iALK5 (20 μM) were injected 
into the subcutaneous tissues on the back. Matrigel plugs were removed 10 days later and analyzed for 
microvascular formation by immunohistochemistry using anti-vWF antibody. (A) Representative gross 
views of Matrigel plugs resected from mice. (B and D) Representative views of anti-vWF immunostained 
sections of Matrigel plugs containing dynasore (left) and iALK5 (right). (C and E) Quantified data of the 
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Figure 8.   Aki et al.
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Figure 12.   Aki et al.
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